February 6, 2026
After cheering the US tariff cut to 18%, markets are back in the volatile zone.
Sensex is down 3.3% from its peak. The BSE Smallcap 250 index has fallen over 12%.
The reality is dawning that we are still worse off than the pre-Trump era.
While these corrections may not come close to a crash, the pain in broader markets is much sharper than what the indices reflect. If you own stocks, I don’t need to tell you this. You lived it.
In a normal market, this seems like an opportunity to look at a historical track record and find value – embark on a search for quality stocks that correct.
However, these times are a little different.
With an uncertain geopolitical climate and erratic nation leaders, the landscape has become a bit shaky for many companies.
While the damage may not be as bad as what a worst-case scenario would have envisioned a few days ago, the trajectory of margins would likely take a hit.
Management may not be so forthcoming about this. Most of them tend to downplay the challenges and choose to talk disproportionately about opportunities.
I’ve shared this before and it’s a good time to reiterate.
With so much uncertainty, it’s worth monitoring what management is doing. This will probably cause a lot less noise than what they or the so-called market experts are saying.
Tracking insider transactions is one of the ways to see what promoters and management are doing. And one company that deserves a mention in this regard is Senores Pharma.
With major economies becoming increasingly protectionist, Indian pharmaceutical exporters, especially generic players, are feeling the pressure.
The traditional script of manufacturing in India, exporting to the US and competing purely on price is unlikely to work in the same way as it did in the past.
Not to mention generic price erosion – with too many players chasing too few molecules – and margins start to evaporate. Even major Indian pharmaceutical names, with decades of export experience, are rethinking the way they operate in regulated markets.
In the middle of this crisis, Senores Pharma has become a player that employs a strategy that seems perfect for such times. The company generates the majority of its sales and profits from the US market, through a compliant facility in the US itself.
The company has focused on low-penetration niche generic drugs with exclusivity, partnered with government-affiliated CDMO customers and embedded itself in the U.S. pharmaceutical supply chain.
With vertical integration through Indian APIs, a shift away from low-margin emerging market models and plans for sterile injectables in the US market, it is not only playing defense but is also ready to move forward.
So how do insiders support this?
For this newly listed company, the promoter share has increased from 45.77% in December 2024 to 45.81% in December 2025. The last purchases through open market purchases were made in the month of December.
During the month, the insiders – effectively the promoters and key management – bought shares worth Rs 86 lakh, at an average price of Rs 814 per share (purchase price ranging from Rs 762 per share to Rs 823 per share). The stock is currently trading at a lower price.
What makes this transaction more interesting is that the promoters have expressed their willingness to inject more.
At the EGM, the promoters are likely to approve the proposal to issue 1.17 million convertible equity warrants at a price of Rs 812 per share by way of preferential issue to the promoter group. This could help infuse even more Rs 95 crore into the company.
Please note that warrants require an upfront payment of 25%, and the remainder in installments within 18 months from the date of allotment. If the promoters make full payment by then, the warrants will be converted into equity. Otherwise, the warrants will be forfeited without any rights attached.
This is an interesting case where the promoters increase their stake at a price much higher than the IPO offer price of Rs 391 per share, and is in stark contrast to Ola, where promoters chose to sell the shares in the open market after it crashed close to 50% of the IPO offer price.
Please note that this is not a recommendation or view on the stock. Nevertheless, it is a stock that deserves to be on your watchlist.
If you found this information helpful, watch my video – The most powerful buying signal.
Kind regards,
Richa Agarwal
Editor and research analyst, Hidden gem
Quantum Information Services Private Limited (Research Analyst)
Richa Agarwal Research Analyst at Equitymaster has been leading the Smallcap Research Desk for more than ten years. She is also editor of the advisory services Hidden Treasure, Phase One Alert and InsiderPro Stocks. Richa’s approach to identifying high-potential stocks is rooted in deep management interactions and on-the-ground research, and in taking cues from insider activity. She has traveled thousands of miles to meet executives and analyze companies in the Indian small and medium space. Its advantage lies in connecting management intent with financial reality.
#cleanest #signal #noisy #market